Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.globenewswire.com/news-release/2023/12/05/2791056/0/en/SOHM-Announces-Business-Outlook-for-2024.html
SOHM Announces Business Outlook for 2024
December 05, 2023 09:30 ET Source: SOHM, Inc.
Source links within the above GlobeNewswire PR:
https://www.chpa.org/about-consumer-healthcare/research-data/otc-sales-statistics
https://www.gminsights.com/industry-analysis/branded-generics-market#:~:text=Branded%20Generics%20Market%20size%20accounted,substantial%20boost%20to%20the%20market.
https://www.visionresearchreports.com/pharmaceutical-cdmo-market/40281#:~:text=The%20global%20pharmaceutical%20CDMO%20market,6.13%25%20from%202023%20to%202032.&text=With%20a%20growth%20rate%20of,share%20in%20the%20CDMO%20market.
https://www.prnewswire.com/news-releases/gene-editing-market-worth-10-6-billion--marketsandmarkets-301877363.html
"The Company is expanding its revenue growth various pharmaceutical and biotech sectors. It has set a 2024 target and is taking steps to achieve it. It wants to excel in cell therapy and gene editing. It expects to earn several million from its business units, including ABBIE. This estimate is based on its internal actions, current opportunities, licensing deals, and kit adoption. This was announced by Mr. Baron Night, CEO and president, and Dr. David Aguilar, COO."
___
hL shmn Baby Pharma .0015
"So absolutely if they are competitively priced."
“I am very proud to launch this facility with our SOHM team members. This Carlsbad facility is conveniently located right at the mid-way between two importing commercial hubs: Los Angeles and San Diego. Our location on major land shipping routes will play an important role in maintaining our competitive pricing edge in material sourcing and final products to our clients. Many people do not know this, but Carlsbad is also the home to many biotech and pharma companies who routinely rely on CDMO operators like SOHM for their bio-manufacturing needs,” says Dr. David Aguilar, COO."
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Announces-New-CDMO-GMP-Manufacturing-Facility-in-Carlsbad-California?id=422243
___
hL shmn
More on the CDMO scene in Carlsbad, CA:
https://www.biopharma-reporter.com/Article/2021/10/14/New-Merck-KGaA-viral-vector-CDMO-plant-opens-in-California?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright
https://www.biopharma-reporter.com/Article/2021/11/30/Long-lead-times-Demand-currently-outstrips-supply-for-contract-manufacturing
https://www.biopharma-reporter.com/Article/2022/02/14/Merck-restructures-to-strengthen-CDMO-business
https://www.prnewswire.com/in/news-releases/merck-completes-new-viral-vector-contract-development-manufacturing-facility-for-gene-therapy-871948996.html
https://www.argonautms.com/ecosystem-partners/
https://www.argonautms.com/
https://www.linkedin.com/in/david-aguilar-ph-d-51b8003a/
https://www.pharmaceuticalcommerce.com/view/sohm-introduces-new-california-manufacturing-facility
__
hL shmn
Higher Lows. Low this week .0013. Low last week .0012. Week before low .0011. Week before that .0010/.0009.
Next week low .0013/.0014?
Progress, imo. Not wiped out.
It was also progress to hit a new 52W High.
https://www.barchart.com/stocks/quotes/SHMN/technical-chart?plot=CANDLE&volume=total&data=DO&density=O&pricesOn=1&asPctChange=0&logscale=0&indicators=BBANDS(20,2);PTP(50);STOSL(14,3);STOFA(14,3);RSI(14,100);CHKMF(20);CHKMF(10);CHKOSC;ACCUM;OBV;MFI(14,100);SMA(20);SMA(50);MACD(12,26,9);SMA(200)&sym=SHMN&grid=1&height=500&studyheight=200
__
hL shmn, good week, respects. imo.
"We are thrilled to associate with SOHM and look forward to having a meaningful long-term association with SOHM, Inc., Said Mr. Vijay Shah, Chairman of Stallion Laboratories Pvt. Ltd. Further Mr. Vijay Shah, Chairman says Stallion Laboratories Pvt. Ltd. owns the ANDA, but have an exclusive distribution agreement with SOHM, Inc. for the USA for the distribution. The product shall be manufactured at our US FDA-approved facility in Ahmedabad, India, and distributed under SOHM's label and NDC numbers, Mr. Vijay Shah, Chairman added."
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Signed-an-Exclusive-Distribution-Agreement-with-India-based-Stallion-Laboratories-Pvt-Ltd-for-Levetiracetam-for?id=398070
__hL shmn
True. The market for LEVETIRACETAM:
"According to a report by Transparency Market Research, the global antiepileptic drugs market, including Levetiracetam, was valued at approximately USD 6 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of around 3.9% from 2021 to 2031. The various clinical and research report notes that the increasing prevalence of epilepsy, the growing use of antiepileptic drugs, and the development of new drugs are some factors driving the market growth."
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Signed-an-Exclusive-Distribution-Agreement-with-India-based-Stallion-Laboratories-Pvt-Ltd-for-Levetiracetam-for?id=398070
https://www.linkedin.com/pulse/levetiracetam-market-size-trends-growth-scope/
https://www.epilepsy.com/tools-resources/seizure-medication-list/levetiracetam
___
They only have exclusive rights from Stallion in the U.S.
Some estimates are $250M USD "United States" market for Levetiracetam.
SOHM states they can capture $3M of that, or more.
Which = .012% of the US Market. Let's see if they can do it, imo.
hL shmn. Do you think it's possible with what they've said, and who is at the helm?
DailyMed - SOHM, NDC Codes, Stallion Labs LEVETIRACETAM:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a688786-879b-4e27-a46a-5c86bbfa1292
Stallion Laboratories Pvt. Ltd :
https://www.linkedin.com/posts/stallion-laboratories-pvt-ltd-3079761a1_usfda-usfdaapproval-anda-activity-7049701335192985600-T5R6/?originalSubdomain=ug
http://www.stallionlabs.com/
http://www.stallionlabs.com/product.php#ANTI-CONVULSANT-ANTI-EPILEPSY-NEUROPATHIC-PAIN
http://www.stallionlabs.com/product-gallery.php
We are thrilled to associate with SOHM and look forward to having a meaningful long-term association with SOHM, Inc., Said Mr. Vijay Shah, Chairman of Stallion Laboratories Pvt. Ltd. Further Mr. Vijay Shah, Chairman says Stallion Laboratories Pvt. Ltd. owns the ANDA, but have an exclusive distribution agreement with SOHM, Inc. for the USA for the distribution. The product shall be manufactured at our US FDA-approved facility in Ahmedabad, India, and distributed under SOHM's label and NDC numbers, Mr. Vijay Shah, Chairman added.
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Signed-an-Exclusive-Distribution-Agreement-with-India-based-Stallion-Laboratories-Pvt-Ltd-for-Levetiracetam-for?id=398070
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172114975
___
hL shmn Baby Pharma.
"The management and leadership are excited about this new product and expect estimated revenues of US $3-5 million annually or plans to capture 5 to 10% of the market share in coming months. "
The "or" is the qualifier.
If we're "expecting" estimated downside of $3M annual Revenues on just LEVETIRACETAM...
...That's almost 10 times 2022 Revenues alone.
This one drug alone, could fund much of SOHM's initiatives...imo. LEVETIRACETAM is important, imo.
hL shmn Baby Pharma.
MDP, I agree that statement was overly optimistic. The only way they could make that statement, and also keep talking about the arrival of the LEVETIRACETAM, is if they have orders/commitments/customers, imo.
Under Baron of the past...I'd say we'll see. Under Aguilar and Rushing, and their accomplishments, I have confidence they will sell the Epilepsy drug, and make good on previous announcements.
We've seen the facility in San Diego inside. We've seen several pallets of something received inside. LEVETIRACETAM has also been announced as "on the way."
They surprised us with a good revenue 3Q. (Comparative to recent years.)
They have turned the corner imo. More Revenue surprises are coming, imo.
Revenue surprises point toward self-sufficiency, profits, and ability to pay debt, overhead, without dilution.
I'm optimistic personally. Agree with your caution too.
Good fortune. hL shmn
Between Nov 29 - Dec 6 LEVETIRACETAM:
"We are expecting to receive our SOHM label Rx products LEVETIRACETAM in next 3/4 weeks. LEVETIRACETAM is a medication that treats seizures (epilepsy). It is a generic medication and is on the World Health Organization’s List of Essential Medicines."
~ Nov 8th, 2023.
"SOHM Inc. Signed an Exclusive Distribution Agreement with India-based Stallion Laboratories Pvt. Ltd. for Levetiracetam for the Treatment of Epilepsy"
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Signed-an-Exclusive-Distribution-Agreement-with-India-based-Stallion-Laboratories-Pvt-Ltd-for-Levetiracetam-for?id=398070
"The management and leadership are excited about this new product and expect estimated revenues of US $3-5 million annually or plans to capture 5 to 10% of the market share in coming months. "
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173238865
___
We've already beaten last years Revs thru 3 Quarters, although small at $383,620.00. I'd say we're on a track to be over $600,000 imo.
Let's hear some announcements on orders for Levetiracetam, etc.
hL shmn Baby Pharma. :)
WTER .32 : https://www.otcmarkets.com/filing/html?id=17085553&guid=I2J-kF3ChkNIdth
https://www.sec.gov/ix?doc=/Archives/edgar/data/1532390/000106299323021510/form8k.htm
__
"...a Nasdaq customer..."
$HIRU upcoming merger docs & all draft SEC filings on the link https://t.co/8fRnXLERy3
— @Hirucorp (@Hirucorpnew) November 27, 2023
Questions or FAQ please email us corporate@otchiru.com we will provide detailed answer. The company doesn't reply to individual requests on X. Formal filing will follow awaiting access codes
.0016 +23.08% Baby Pharma sprouting, imo.
hL shmn
What Is a CDMO (and Why Do You Need One)?
https://ascendiapharma.com/newsroom/2021/06/30/pharmaceutical-cdmos
____
SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California
https://www.globenewswire.com/news-release/2023/11/21/2784138/0/en/SOHM-Announces-New-CDMO-GMP-Manufacturing-Facility-in-Carlsbad-California.html
"...Carlsbad is also the home to many biotech and pharma companies who routinely rely on CDMO operators like SOHM..."
"...manufacture for CDMO clients whose orders are now arriving for year-end-2023.”
" $SHMN Launches Carlsbad-Based CDMO GMP Manufacturing Facility "
BioMedNewsBreaks – $SHMN Launches Carlsbad-Based CDMO GMP Manufacturing Facility https://t.co/nkrPJVgLSo pic.twitter.com/umu8AZRH1y
— MissionIR (@MissionIR) November 22, 2023
BioMedNewsBreaks – $SHMN Launches Carlsbad-Based CDMO GMP Manufacturing Facility https://t.co/K3wd1nezzI pic.twitter.com/Rp5C6dyEFS
— IBN (InvestorBrandNetwork) (@IBNMediaNetwork) November 22, 2023
BioMedNewsBreaks – $SHMN Launches Carlsbad-Based CDMO GMP Manufacturing Facility https://t.co/a1FGYFZIoS pic.twitter.com/gBcBBoRFW7
— BioMedWire (@BioMedWire) November 22, 2023
Eric Furman, Ph.D. Knobbe Martens Sohm Intellectual Property Attorney:
https://www.knobbe.com/attorneys/eric-furman
Awards & Honors
Named amongst Top 30 for Most Active Attorneys in Biotech in Patexia's Patent Intelligence 2023 Report
Named one of the "World's Leading Patent Professionals" in the Patent 1000 guide by Intellectual Asset Management (IAM) magazine for Prosecution (2020-2023)
Named among the "Top 25 Intellectual Property Portfolio Managers & Patent Prosecutors" by the Daily Journal in 2015.
https://www.knobbe.com/blog/merck-sues-federal-government-over-medicare-drug-price-negotiation-program
Wed, 06/07/2023 - 12:00 | Brianne M. Kingery & Eric Furman, Ph.D.
Recent Update on Patent Trial Practice Guide
Tue, 08/28/2018 - 12:00 | Eric Furman, Ph.D.
https://www.knobbe.com/news/2018/08/recent-update-patent-trial-practice-guide?blog_top=1281
Articles (Resources)
https://www.knobbe.com/attorneys/eric-furman
Knobbe Martens Webinar Series:
Strategic Considerations in Addressing Obviousness Rejections under Section 103
December 03, 2020 | Mauricio Uribe & Eric Furman, Ph.D. & Vlad Teplitskiy
https://www.knobbe.com/news/knobbe-martens-webinar-series-strategic-considerations-addressing-obviousness-rejections-under
https://www.linkedin.com/in/eric-furman-9053b29/
Carlsbad, California, United States
__
hL shmn
Pink Limited: "...and voila it will be there!"
Thanks for the reply. Not that it's a huge deal, but it's due Nov 14th. (45 days after the Quarter ended since there were 31 days in October) We're looking for lots of new information in that 3Q by the 14th. Including the new debt, and how much WTER owes? Thank you. $hiru
— Dave (@hardlesson1) November 10, 2023
"$HIRU Q3 looks good in our opinion. OTC froze the acc to update records due to incoming merger & step up change of control for next few weeks. See Q3 on http://otchiru.com/q3 until OTC updates records."
$HIRU Q3 looks good in our opinion. OTC froze the acc to update records due to incoming merger & step up change of control for next few weeks. See Q3 on https://t.co/y2mdHAk2cd until OTC updates records.
— @Hirucorp (@Hirucorpnew) November 21, 2023
For whatever reason, they stealthily added the Carlsbad facility and it's already cGMP ready, and December is in 10 days.
1Q 2024 is in 40 days.
My guess is that San Diego wasn't going to be large enough for all initiatives.
They need a facility for the topicals, etc.
They need a facility for the ABBIE kits. ("large scale")
Thanks to Dewey Rushing, they already have the cGMP facility in Carlsbad.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173082914
My guess is that the SanDiego facility needs tweaked probably after FDA inspection, thus the need for "renovations" as mentioned in today's PR. The inspection may have required some additions for "clean rooms" etc, who knows...William Dewey Rushing knows, as he has been there and knows what needs to be done to satisfy FDA. SanDiego might also need to be tweaked for production/capacity/efficiency?
Distraction? My guess is no.
This isn't the old SHMN, with Baron trying to do what he could.
This is the new SOHM.
Dr. David Aguilar has been there, with Kiromic Biopharma. (Others)
Wm. Dewey Rushing (former FDA, and current contractor) has been there, with various inspections at Domestic and International Pharma.
Myth, We don't know what Carlsbad is costing us in Rent/Lease, as it hasn't been itemized or discussed by Management, to my knowledge.
We are on the cusp of production, and we already have client orders. (To be formally announced/quantified.)
All imo. hL
Key Points for me: CHINO HILLS, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today its new manufacturing facility at Carlsbad.
SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California.
The company is excited to announce the opening of a new facility in Carlsbad to meet the growing demand for its products. This facility will handle the orders that SOHM has received and expects to receive in the near future, while its main facility in downtown San Diego undergoes renovation to become fully operational. SOHM aims to complete the engineering batches produced in the San Diego facility by Q1 2024. This expansion is part of the company’s strategic plan to enhance its production capacity and efficiency.
The new Carlsbad, California, facility will feature adequate space to manufacture topical products and SOHM’s operations, and 2,500 square feet allocated to storage of finished products. (CDMO: Contract Development and Manufacturing Organization.)
This facility will have an initial daily capacity of 500 gallons (1,892 liters) with initial manufactured products of topicals but will be expected to add soft-gel suppositories to its capacity by end of Q1 2024 /beginning of Q2 2024.
As of this press release, the facility is near-final. Full cGMP manufacturing capacity is expected to be completed by December 2023. (10 days from now. hL)
The bio and pharma contract development and manufacturing (“CDMO”) market is $223 billion as of 2023 and is expected to grow to $309 billion by 2028, implying a 6.74% CAGR between 2018 - 2028 (compounded annual growth rate). The largest CDMO market is North America with the largest production market being Asia, according to Mordor Intelligence.
Source: Link to Mordor Intelligence.com (industry report 2023).
ABBIE is SOHM’s non-viral gene-editing bio-kits. Large-scale commercial manufacturing of ABBIE gene editing kits will be supported in SOHM’s Southern California manufacturing facilities.
“I am very proud to launch this facility with our SOHM team members. This Carlsbad facility is conveniently located right at the mid-way between two importing commercial hubs: Los Angeles and San Diego. Our location on major land shipping routes will play an important role in maintaining our competitive pricing edge in material sourcing and final products to our clients. Many people do not know this, but Carlsbad is also the home to many biotech and pharma companies who routinely rely on CDMO operators like SOHM for their bio-manufacturing needs,” says Dr. David Aguilar, COO.
Dr. Aguilar continues, “In 12 months, our Carlsbad facility will be expecting to manufacture 70% Rx and 30% OTC (over-the-counter) products. This facility will be able to meet all of our short-term SOHM brand Rx topical and OTC product manufacturing with 100% allocated to manufacture for CDMO clients whose orders are now arriving for year-end-2023.”
Key Milestone:
-- Engineering batch of topical branded generic completed within this financial year/2023
-- Initial released batch to client by 1Q 2024
SOHM management looks forward to announcing more updates on this facility in the upcoming year-end-2023 report and thanks you for your continued support and trust in the company.
___
hL ... Baby Pharma at .0013?
https://www.globenewswire.com/news-release/2023/11/21/2784138/0/en/SOHM-Announces-New-CDMO-GMP-Manufacturing-Facility-in-Carlsbad-California.html
Carlsbad Facility News: https://www.globenewswire.com/news-release/2023/11/21/2784138/0/en/SOHM-Announces-New-CDMO-GMP-Manufacturing-Facility-in-Carlsbad-California.html
__
Now we know why "Carlsbad" was mentioned in the 3Q:
_
hL Now we have (2) cGMP/FDA Facilities in the pipeline. Incredible, imo.
"The Company expects the following products are ready to be commercialized as of September 2023."
__
The above addition to page 10 of the most recent disclosure is also significant, imo.
https://www.otcmarkets.com/otcapi/company/financial-report/386173/content
hL shmn
Knobbe Martens (IP Attorney) added as additional Counsel:
https://www.knobbe.com/
https://www.knobbe.com/services/industry-groups/pharmaceuticals
https://www.knobbe.com/services/industry-groups/medical-devices-procedures
https://www.otcmarkets.com/stock/SHMN/profile
___
My guess is this IP Attorney is stemming from ABBIE. Impressed with the Knobbe Martens website.
Aguilar and Rushing, Night, doing their jobs, imo.
hL shmn
Changes at Georgia SOS:
https://ecorp.sos.ga.gov/BusinessSearch/BusinessInformation?businessId=786057&businessType=Domestic%20Profit%20Corporation&fromSearch=True
$HIRU is updating Georgia Sos with new officers/directors, stake holders (shareholders of more than 4.9% and 10% pursuant to OTC filings) pursuant to SEC/OTC filings
— @Hirucorp (@Hirucorpnew) November 16, 2023
Between Nov 29 - Dec 6 LEVETIRACETAM:
"We are expecting to receive our SOHM label Rx products LEVETIRACETAM in next 3/4 weeks. LEVETIRACETAM is a medication that treats seizures (epilepsy). It is a generic medication and is on the World Health Organization’s List of Essential Medicines."
~ Nov 8th, 2023.
"SOHM Inc. Signed an Exclusive Distribution Agreement with India-based Stallion Laboratories Pvt. Ltd. for Levetiracetam for the Treatment of Epilepsy"
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Signed-an-Exclusive-Distribution-Agreement-with-India-based-Stallion-Laboratories-Pvt-Ltd-for-Levetiracetam-for?id=398070
"According to a report by Transparency Market Research, the global antiepileptic drugs market, including Levetiracetam, was valued at approximately USD 6 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of around 3.9% from 2021 to 2031. The various clinical and research report notes that the increasing prevalence of epilepsy, the growing use of antiepileptic drugs, and the development of new drugs are some factors driving the market growth.
Our LEVETIRACETAM will be available through pharmacies and healthcare providers. Patients should speak to their doctor to determine if this medication is right for them.
The management and leadership are excited about this new product and expect estimated revenues of US$3-5 million annually or plans to capture 5 to 10% of the market share in coming months. The company expects its introduction in the market in the next two months."
____
The below link doesn't exist anymore regarding various delays that have been talked about here in detail, including the delay of the Epilepsy drug, due to various State Licensing requirements/approvals, something to that effect. But, now the Epilepsy drug is almost here.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172231426
https://www.sohm.com/2023/06/28/sohm-reports-on-half-year-updates-and-future-plans-for-2023/
SOHM Reports on Half-Year Updates and Future Plans for 2023. https://t.co/XLatgxZWhN $SHMN
— SOHM, Inc. (@sohminc) June 28, 2023
Looks like a delicious word salad, just add some good Olive Oil.
hL :)
:) Funny stuff. Soap. Opera. We could sell some laundry detergent in here.
Also, looks like some interesting updates to the OTC profile:
Employees up, from 5 to 11.
Added Officer: William Dewey Rushing, VP, Manufacturing
🚨 $SHMN
— OTC Updates (@OtcUpdates) November 14, 2023
💰0.0014
Pink Current, AS: 3.0B, OS: 1.6B, US: 1.3B
Number of Employees Updated:
🔴 5
🟢 11
Officer(s) Added:
🟢William Dewey Rushing, VP, Manufacturing
https://t.co/TE0NqcXT8Z
:) The PR hit Etrade right at 9:30am yesterday on my L2 platform. I also figured since the Q was out, they might PR the results.
But I was surprised the Q wasn't mentioned, and instead we got the PR about the chewables.
I've also noticed they got back to using globenewswire.com. So their PR's are now getting picked up by more people.
https://www.globenewswire.com/search/keyword/sohm?pageSize=10
hL. Shmn
Was that you know who?
hL
:) Thank you, good to know. Just got caught up on X, I think. Man, he's on a roll this weekend. :)
hL
Thanks for the reply. Not that it's a huge deal, but it's due Nov 14th. (45 days after the Quarter ended since there were 31 days in October) We're looking for lots of new information in that 3Q by the 14th. Including the new debt, and how much WTER owes? Thank you. $hiru
— Dave (@hardlesson1) November 10, 2023
It will allow plenty of time over the weekend to digest whatever is in it, good, bad, or otherwise. Also, if he is to be awarded shares at some point, (because of the defaulted loan he claims, or for the New Management) that will require that "interim management/consultant" will have to change the AS at Georgia SOS.
Kathryn needs to be removed on Georgia SOS and new addresses added.
The TA will need to be informed of SS changes, and verify.
3Q will need to post at OTCM.
...and is Kathryn selling her Control Block of Preferred...
Lots of things are needing to come together all in the next few days, imo.
Then the future of HIRU will be clear as mud. :)
hL imo.
$HIRU will release the anticipated Mini Super 8k of corporate affairs and S/h FAQ of Ex management affairs corporate status after the market closes.
— @Hirucorp (@Hirucorpnew) November 10, 2023
Exactly! I said the same thing out loud this morning when I read that Tweet.
Crazy stuff.
hL
Eyes here for today's anticipated 8K:
https://www.sec.gov/edgar/browse/?CIK=925779
$Hiru a comprehensive Mini Super 8k type filing will be filed by Friday latest (or as soon as possible) addressing most shareholders FAQ + corporate actions incoming merger new key staff & various positive results achieved so far.
— @Hirucorp (@Hirucorpnew) November 8, 2023
Revised Ahem:
If the company is going to .005 to .02 then why you selling? Just ride it up with the rest of us?
— Portcitybob (@Portcitybob) November 9, 2023
It's not a saw blade, or a cliff edge. It's a stock trade.
Danger, danger, danger, is what you say to a toddler so they don't put their hands on a hot stove.
But of course we all understand your caution.
hL
Ahem.
If the company is going to .005 to .02 then why you selling? Just ride it up with the rest of us?
— Portcitybob (@Portcitybob) November 9, 2023
Wow. .0019, +111% today. hL